Global Human Insulin Market Report and Forecast 2024-2032

Global Human Insulin Market Outlook

The global human insulin market value was USD 20.89 billion in 2023, driven by the rising prevalence of diabetes across the globe. The global human insulin market share is anticipated to grow at a CAGR of 3.4% during the forecast period of 2024-2032 to achieve a value of USD 28.22 billion by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Rising Incidence of Diabetes in North America to Aid the Market Growth of Human Insulin

The market for human insulin is expected to be driven by the growing demand from the North America region over the forecast period. This could be attributed to the rising incidence of diabetes and the increasing geriatric population, which are majorly contributing to the rising demand for human insulin in the region. On the basis of revenue, many countries in Europe like Germany, France, and Italy are predicted to contribute considerably to the growth of the human insulin industry over the forecast period. Meanwhile, the Asia Pacific region is expected to be a favourable market for human insulin over the forecast period. This could be ascribed to the growing research and development activities undertaken by various organisations and rising government initiatives in the region.

Human Insulin: Market Segmentation

Human insulin is referred to the synthetic insulin, which is grown in the laboratory and simulates the insulin in humans. The function of insulin is to regulate fat and carbohydrate metabolism in the body. It was developed through the 1960s and 1970s and finally approved for pharmaceutical use in 1982.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

On the basis of product type, the market is divided into:

• Drugs
• Delivery Device

Based on type, the industry can be segmented into:

• Insulin Analogs and Biosimilars
• Delivery Device

Insulin analogs and biosimilars is further divided on the basis of types into long acting, rapid acting, and pre-mixed, whereas delivery device is divided into intermediate-acting, short-acting, pre-mixed.

By brand, the industry is categorised into:

• NovoRapid/Novolog
• Humalog
• Insuman
• Humulin
• Lantus
• Actrapid, Insulatard, and Mixtard
• Others

On the basis of delivery service, the industry is segregated into:

• Pens
• Syringes
• Pen Needles
• Others

Based on applications, the industry is divided into:

• Type 1
• Type 2

The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Rising Investments in R&D Activities to Aid the Market Growth of Human Insulin

The market for human insulin is driven by the rising cases of diabetes and obesity across the globe, which are the resultants of changing lifestyles and unhealthy consumption of sugar in various food and beverages. In addition, the rising investments in research and development activities by several organisations have led to an advanced and easier way of injecting insulin, which is also boosting the market growth of human insulin. Moreover, the introduction of the safety pen devices and pen needles for effective delivery of insulin is propelling the global market forward. Further, growing awareness of diabetes is expected to bolster the demand in the human insulin industry.

Key Industry Players in the Global Human Insulin Market

The report gives a detailed analysis of the following key players in the global human insulin market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

• Novo Nordisk A/S
• Biocon Limited
• Sanofi S.A.
• Pfizer Inc.
• Eli Lilly and Company
• Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

Key Highlights of the Report